| 1 |
Campbell BCV, De Silva DA, Macleod MR, et al. Ischaemic stroke [J]. Nat Rev Diseas Primers, 2019, 5(1): 70.
|
| 2 |
An SJ, Kim TJ, Yoon BW. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update [J]. J Stroke, 2017,19(1): 3-10.
|
| 3 |
Levine DA, Galecki AT, Langa KM, et al. Trajectory of cognitive decline after incident stroke [J]. JAMA, 2015, 314(1): 41-51.
|
| 4 |
Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the global burden of disease study 2013 [J]. Lancet Neurol, 2016, 15(9): 913-924.
|
| 5 |
Leppert MH, Campbell JD, Simpson JR, et al. Cost-effectiveness of intra-arterial treatment as an adjunct to intravenous tissue-type plasminogen activator for acute ischemic stroke [J]. Stroke, 2015, 46(7): 1870-1876.
|
| 6 |
Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ecass, atlantis, ninds, and epithet trials [J]. Lancet, 2010, 375(9727): 1695-1703.
|
| 7 |
Kim JY, Bae HJ. Spontaneous intracerebral hemorrhage: management [J]. J Stroke, 2017, 19(1): 28-39.
|
| 8 |
O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke [J]. Ann Neurol, 2006, 59(3): 467-477.
|
| 9 |
Macrez R, Ali C, Toutirais O, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies [J]. Lancet Neurol, 2011, 10(5): 471-480.
|
| 10 |
Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation [J]. Nat Med, 2011, 17(7): 796-808.
|
| 11 |
Seizer P, Ochmann C, Schonberger T, et al. Disrupting the EMMPRIN(CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion [J]. Arterioscl Throm Vas, 2011, 31(6): 1377-1386.
|
| 12 |
Agrawal SM, Yong VW. The many faces of EMMPRIN - roles in neuroinflammation [J]. Biochim Biophys Acta, 2011, 1812(2): 213-219.
|
| 13 |
Guo H, Li R, Zucker S, et al. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface [J]. Cancer Res, 2000, 60(4): 888-891.
|
| 14 |
Patrizz A, Doran SJ, Chauhan A, et al. EMMPRIN/CD147 plays a detrimental role in clinical and experimental ischemic stroke [J]. Aging (Albany NY), 2020, 12(6): 5121-5139.
|
| 15 |
Jin R, Xiao AY, Chen R, et al. Inhibition of CD147 (cluster of differentiation 147) ameliorates acute ischemic stroke in mice by reducing thromboinflammation [J]. Stroke, 2017, 48(12): 3356-3365.
|
| 16 |
Miyauchi T, Masuzawa Y, Muramatsu T. The basigin group of the immunoglobulin superfamily: complete conservation of a segment in and around transmembrane domains of human and mouse basigin and chicken HT7 antigen [J]. J Biochem, 1991, 110(5): 770-774.
|
| 17 |
Biswas C, Zhang Y, DeCastro R, Guo H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily [J]. Cancer Res, 1995, 55(2): 434-439.
|
| 18 |
Yu XL, Hu T, Du JM, et al. Crystal structure of HAB18G/CD147: Implications for immunoglobulin superfamily homophilic adhesion [J]. J Biol Chem, 2008, 283(26): 18056-18065.
|
| 19 |
Knutti N, Kuepper M, Friedrich K, et al. Soluble extracellular matrix metalloproteinase inducer (EMMPRIN,EMN) regulates cancer-related cellular functions by homotypic interactions with surface CD147 [J]. FEBS J, 2015, 282(21): 4187-4200.
|
| 20 |
Miyauchi T, Kanekura T, Yamaoka A, Ozawa M, et al. Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class ii antigen [J]. J Biochem, 1990, 107(2): 316-323.
|
| 21 |
Kawano H, Tono T, Kadomatsu K, et al. Expression of basigin, a member of the immunoglobulin superfamily, in the mouse cochlea [J]. ORL J Otorhinolaryngol Relat Spec, 2003, 65(6): 327-331.
|
| 22 |
Schlosshauer B, Herzog KH. Neurothelin: an inducible cell surface glycoprotein of blood-brain barrier-specific endothelial cells and distinct neurons [J]. J Cell Biol, 1990, 110(4): 1261-1274.
|
| 23 |
Igakura T, Kadomatsu K, Taguchi O, et al. Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier [J]. Biochem Biophys Res Commun, 1996, 224(1): 33-36.
|
| 24 |
Naruhashi K, Kadomatsu K, Igakura T, et al. Abnormalities of sensory and memory functions in mice lacking bsg gene [J]. Biochem Biophys Res Commun, 1997, 236(3): 733-737.
|
| 25 |
Mroczko B, Groblewska M, Barcikowska M, et al. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study [J]. J Alzheimers Dis, 2013, 37(2): 273-283.
|
| 26 |
Lattanzi S, Di Napoli M, Ricci S, et al. Matrix metalloproteinases in acute intracerebral hemorrhage [J]. Neurotherapeutics, 2020, 17(2): 484-496.
|
| 27 |
Liu Y,Li Z,Khan S, et al. Neuroprotection of minocycline via inhibition of EMMPRIN in intracerebral hemorrhage in mice [J].Neurosci Lett, 2021, 764: 1-12.
|
| 28 |
Yurchenko V, Constant S, Eisenmesser E, et al. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics [J]. Clin Exp Immunol, 2010, 160(3): 305-317.
|
| 29 |
Damsker JM, Okwumabua I, Pushkarsky T, et al. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis [J]. Immunology, 2009, 126(1): 55-62.
|
| 30 |
Agrawal SM, Silva C, Tourtellotte WW, et al. EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis [J]. J Neurosci, 2011, 31(2): 669-677.
|
| 31 |
Wang Y, Liu G, Hong D, et al. White matter injury in ischemic stroke [J]. Prog Neurobiol, 2016, 141(1): 45-60.
|
| 32 |
Liu S, Jin R, Xiao AY, et al. Inhibition of CD147 improves oligodendrogenesis and promotes white matter integrity and functional recovery in mice after ischemic stroke [J]. Brain Behav Immun, 2019, 82(12): 13-24.
|
| 33 |
Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the ninds t-PA stroke trial [J]. Stroke, 1997, 28(46): 2119-2125.
|
| 34 |
Kanazawa M, Takahashi T, Nishizawa M, et al. Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke [J]. J Atheroscler Thromb, 2017, 24(3): 240-253.
|
| 35 |
Tu Y, Fu J, Wang J, et al. Extracellular matrix metalloproteinase inducer is associated with severity of brain oedema following experimental subarachnoid haemorrhage in rats [J]. J Int Med Res, 2012, 40(3): 1089-1098.
|
| 36 |
Agrawal SM, Silva C, Wang J, et al. A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: Relevance to multiple sclerosis [J]. J Neuroinflammation, 2012, 9: 64,
|
| 37 |
Linares G, Mayer SA. Hypothermia for the treatment of ischemic and hemorrhagic stroke [J]. Crit Care Med, 2009, 37(7): S243-S249.
|
| 38 |
Krieger DW, De Georgia MA, Abou-Chebl A, et al. Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke [J]. Stroke, 2001, 32(8): 1847-1854.
|
| 39 |
Burggraf D, Martens HK, Hamann GF. Hypothermia reduces influence of matrix metalloproteinase induction by emmprin in experimental focal cerebral ischemia [J]. J Cereb Blood Flow Metab, 2005, 25(1): S20.
|
| 40 |
Winchester LJ, Veeranki S, Givvimani S, et al. Homocysteine elicits an M1 phenotype in murine macrophages through an EMMPRIN-mediated pathway [J]. Can J Physiol Pharmacol, 2015, 93(7): 577-584.
|